We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Ulcerative pyoderma gangrenosum is a rare disease with ...

People who have an inflammatory bowel disease like ulcerative colitis often have problems caused by inflammation in other parts of their bodies. One of these is a skin condition called pyoderma ...

Please provide your email address to receive an email when new articles are posted on . A minimal important difference of 7-day pain scores was a 2-point improvement on an 11-point scale. A 2-point ...

Vilobelimab is a first-in-class anti-human complement factor C5a monoclonal antibody. The Food and Drug Administration (FDA) has granted Fast Track designation to vilobelimab for the treatment of ...

InflaRx ( (IFRX)) has shared an announcement. On December 30, 2025, InflaRx reported detailed Phase 3 data analyses for vilobelimab in pyoderma gangrenosum (PG), a rare, difficult-to-treat ulcerative ...

InflaRx presented data analyses from a terminated Phase 3 study on the potential treatment for rare skin condition.

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...